These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 1511541)

  • 21. The role of colesevelam hydrochloride in hypercholesterolemia and type 2 diabetes mellitus.
    Brunetti L; Hermes-Desantis ER
    Ann Pharmacother; 2010; 44(7-8):1196-206. PubMed ID: 20551301
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pitavastatin: a new HMG-CoA reductase inhibitor.
    Wensel TM; Waldrop BA; Wensel B
    Ann Pharmacother; 2010 Mar; 44(3):507-14. PubMed ID: 20179258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical evaluation of a selective inhibitor of cholesterol synthesis: pravastatin].
    Alessandri C; Peverini F
    Minerva Med; 1992 Nov; 83(11):677-93. PubMed ID: 1461539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients.
    Miyake Y; Shouzu A; Nishikawa M; Yonemoto T; Shimizu H; Omoto S; Hayakawa T; Inada M
    Arzneimittelforschung; 1999 Apr; 49(4):324-9. PubMed ID: 10337451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of pravastatin as a hypolipidemic agent in patients with polygenic hypercholesterolemia.
    Aldrete-Velasco J; Casanova JM; Mejía P; Martínez P
    Arch Med Res; 1992; 23(3):117-22. PubMed ID: 1308800
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In-vitro effect of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors on non-hepatic LDL receptor activity: evidence of lack of stimulatory effect of pravastatin.
    Pedreño J; Sánchez JL; Zambón D; Ros E
    Coron Artery Dis; 1994 Dec; 5(12):971-7. PubMed ID: 7728297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia.
    Illingworth DR; Bacon S
    Am J Cardiol; 1987 Oct; 60(12):33G-42G. PubMed ID: 3314447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pravastatin reduces thrombogenicity by mechanisms beyond plasma cholesterol lowering.
    Casani L; Sanchez-Gomez S; Vilahur G; Badimon L
    Thromb Haemost; 2005 Nov; 94(5):1035-41. PubMed ID: 16363247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pravastatin, a new cholesterol synthesis inhibitor for lowering increased serum cholesterol].
    Hoppichler F; Lechleitner M; Patsch JR
    Z Gesamte Inn Med; 1992 Nov; 47(11):523-7. PubMed ID: 1462678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pitavastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia.
    Ahmad H; Cheng-Lai A
    Cardiol Rev; 2010; 18(5):264-7. PubMed ID: 20699675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia.
    McTavish D; Sorkin EM
    Drugs; 1991 Jul; 42(1):65-89. PubMed ID: 1718686
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pravastatin: a review of its use in elderly patients.
    Bang LM; Goa KL
    Drugs Aging; 2003; 20(14):1061-82. PubMed ID: 14651445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pravastatin sodium, a new HMG-CoA reductase inhibitor.
    Raasch RH
    DICP; 1991 Apr; 25(4):388-94. PubMed ID: 1926908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination drug therapy with HMG CoA reductase inhibitors and bile acid sequestrants for hypercholesterolemia.
    Erkelens DW
    Cardiology; 1990; 77 Suppl 4():33-8. PubMed ID: 2073670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HMG-CoA reductase inhibitors: a look back and a look ahead.
    Davignon J; Montigny M; Dufour R
    Can J Cardiol; 1992 Oct; 8(8):843-64. PubMed ID: 1423005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of pravastatin on serum lipids, apolipoproteins and lipoprotein (a) in patients with non-insulin dependent diabetes mellitus.
    Umeda F; Watanabe J; Inoue K; Hisatomi A; Mimura K; Yamauchi T; Sako Y; Kunisaki M; Tajiri Y; Nawata H
    Endocrinol Jpn; 1992 Feb; 39(1):45-50. PubMed ID: 1535040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapy with HMG CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity.
    Pazzucconi F; Dorigotti F; Gianfranceschi G; Campagnoli G; Sirtori M; Franceschini G; Sirtori CR
    Atherosclerosis; 1995 Oct; 117(2):189-98. PubMed ID: 8801864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HMG-CoA reductase inhibitor augments the serum total cholesterol-lowering effect of human adipose tissue-derived multilineage progenitor cells in hyperlipidemic homozygous Watanabe rabbits.
    Saga A; Okura H; Soeda M; Tani J; Fumimoto Y; Komoda H; Moriyama M; Moriyama H; Yamashita S; Ichinose A; Daimon T; Hayakawa T; Matsuyama A
    Biochem Biophys Res Commun; 2011 Aug; 412(1):50-4. PubMed ID: 21806964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
    Desager JP; Horsmans Y
    Clin Pharmacokinet; 1996 Nov; 31(5):348-71. PubMed ID: 9118584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors.
    Kleinveld HA; Demacker PN; De Haan AF; Stalenhoef AF
    Eur J Clin Invest; 1993 May; 23(5):289-95. PubMed ID: 8354335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.